{"denoms":[{"counts":[{"groupId":"BG000","value":"47"}],"units":"Participants"}],"groups":[{"description":"All regimens were analyzed together.\n\nStandard of Care (SOC) Chemotherapy or Standard of Care (SOC) Chemotherapy + total body irradiation\n\nSOC chemotherapy or SOC chemotherapy + total body irradiation (TBI) of one of the following regimens:\n\nRegimen I: Patients receive fludarabine phosphate IV and busulfan IV.\n\nRegimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV.\n\nRegimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV.\n\nRegimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV.\n\nRegimen V: Patients receive carmustine IV, etoposide IV, cytarabine IV, and melphalan IV. Some patients also receive rituximab IV.\n\nRegimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI.","id":"BG000","title":"All Participants"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"20","upperLimit":"70","value":"53"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"30"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}